ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis

seekingalpha2021-10-08

Update: Shares surge 80% in morning trading as trading resumed after FDA approval. ChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

Stripey
2021-10-09
Stripey
Miss it at $30
SPOT_ON
2021-10-09
SPOT_ON
Like n follow
JimmyT
2021-10-08
JimmyT
Ok
HappySheep
2021-10-08
HappySheep
[Miser] [Miser] [Miser]
Galaxy121678
2021-10-08
Galaxy121678
[强]
- Karxun:
  Good

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1100113443?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-08 21:25","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1100113443","market":"us","top_or_hot":-1,"title":"ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis","media":"seekingalpha","content":"<div>\n<p>Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective ...</p>\n\n<a href=\"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemoCentryx's stock jumps 88% on FDA approval of TAVNEOS for treatment of vasculitis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-08 21:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective ...</p>\n\n<a href=\"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CCXI","symbol_name":"ChemoCentryx","start_time":0,"source_url":"https://seekingalpha.com/news/3750870-fda-approves-chemocentryxs-tavneosfor-treatment-of-vasculitis","article_id":"1100113443","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100113443","pubTimestamp":1633699552,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASD","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CCXI":"ChemoCentryx"},"translate_title":"在FDA批准TAVNEOS治疗血管炎后，Chemocentryx的库存飙升88%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CCXI":0.9},"content_text":"Update: Shares surge 80% in morning trading as trading resumed after FDA approval.\nChemoCentryx(NASDAQ:CCXI)announcesthat the FDA has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), in combination with standard therapy.\nThe approval was supported by the results of the Phase III ADVOCATE trial. The study met its primary endpoints of disease remission at 26 weeks and sustained remission at 52 weeks.\nTAVNEOS (avacopan) is also approved for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. The regulatory decision in Europe following the EMA review is expected by the end of 2021.\nANCA-associated vasculitis is a systemic autoimmune disease, resulting in organ damage and failure, with the kidney as the major target, and is often fatal if not treated.\nCCXI shares tumbled 6% in premarket before they were halted for trading, which will resume at 7:30 am ET.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":821269842,"gmtCreate":1633748386018,"gmtModify":1633748386143,"author":{"id":"4096341081825100","authorId":"4096341081825100","name":"Stripey","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"4096341081825100","authorIdStr":"4096341081825100"},"htmlText":"Miss it at $30","listText":"Miss it at $30","text":"Miss it at $30","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821269842","repostId":1100113443,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":821817927,"gmtCreate":1633729203355,"gmtModify":1633729211565,"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"htmlText":"Like n follow&nbsp;","listText":"Like n follow&nbsp;","text":"Like n follow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821817927","repostId":1100113443,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":821161406,"gmtCreate":1633706230878,"gmtModify":1633706231306,"author":{"id":"3581661369298834","authorId":"3581661369298834","name":"JimmyT","avatar":"https://static.tigerbbs.com/748bb288232d8c7092b92b303f282d6e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581661369298834","authorIdStr":"3581661369298834"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821161406","repostId":1100113443,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":821344703,"gmtCreate":1633701996543,"gmtModify":1633702061648,"author":{"id":"3581932792448241","authorId":"3581932792448241","name":"HappySheep","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3581932792448241","authorIdStr":"3581932792448241"},"htmlText":"[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","listText":"[Miser]&nbsp;[Miser]&nbsp;[Miser]&nbsp;","text":"[Miser] [Miser] [Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/821344703","repostId":1100113443,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":821321269,"gmtCreate":1633700430286,"gmtModify":1633700587897,"author":{"id":"4087215268151120","authorId":"4087215268151120","name":"Galaxy121678","avatar":"https://static.tigerbbs.com/b0cab941d047dcba4893f77a2987c5c6","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4087215268151120","authorIdStr":"4087215268151120"},"htmlText":"[强]&nbsp;","listText":"[强]&nbsp;","text":"[强]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/821321269","repostId":1100113443,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6134027,"gmtCreate":1633701436856,"gmtModify":1634718536563,"authorId":3557226916148056,"author":{"id":3557226916148056,"idStr":"3557226916148056","authorId":3557226916148056,"name":"Karxun","avatar":"https://static.tigerbbs.com/87ed84363df8cc411fdf60c3f6eace23","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":821321269,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":90,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100113443"}